

November 4, 2005

Press Release

Aventis Pharma Ltd.
Daiichi Sankyo Co., Ltd.

**DISCONTINUATION OF MARKETING ALLIANCE
FOR KETOLIDE ANTIBIOTICS, “Ketek® TABLETS 300MG”**

Aventis Pharma Ltd., part of the sanofi-aventis Group (president: Philippe Fauchet, head office: Shinjuku-ku, Tokyo) (hereinafter Aventis), and Sankyo Co. Ltd. (president; Yasuhiro Ikegami, headquarters: Chuo-ku, Tokyo) (hereinafter Sankyo), the subsidiary company of Daiichi Sankyo Co. Ltd. (president; Takashi Shoda, headquarters: Chuo-ku, Tokyo), announced today that both companies agreed to discontinue the marketing alliance of “Ketek® Tablets 300mg” (generic name: telithromycin), ketolide antibiotic from January 1, 2006.

Ketek, the first in a new class of antibiotics known as the ketolides, was specifically designed to treat community-acquired respiratory tract infections. Against *Streptococcus pneumoniae* bacteria, for example, Ketek has activity even when other antibiotics such as penicillin, erythromycin, and related drugs are ineffective. Ketek is indicated for the treatment of pharyngitis/laryngitis, tonsillitis, acute bronchitis, pneumonia, secondary infections of chronic respiratory disease, sinusitis, periodontitis, pericoronitis, jaw arthritis.

###